Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30088442 | 1.00 | ENPP2 (0.41) | ENPP2PTGS2KCNH2FYNMAP4K4 | |
| SCHEMBL27635242 | 0.86 | KCNH2 (0.48) | PTGS2KCNH2FYNMAP4K4MINK1 | |
| SCHEMBL23001265 | 0.82 | CHRNB2 (0.37) | — | |
| SCHEMBL2657934 | 0.80 | HTT (0.41) | PTGS2KCNH2 | |
| SCHEMBL2173113 | 0.79 | GAA (0.44) | KCNH2 | |
| SCHEMBL7776146 | 0.78 | CA2 (0.52) | — | |
| SCHEMBL1843623 | 0.78 | ALDH1A1 (0.44) | — | |
| SCHEMBL8313419 | 0.78 | ENPP2 (0.41) | ENPP2PTGS2LOXLOXL2 | |
| SCHEMBL2636788 | 0.78 | SMN1; SMN2 (0.39) | — | |
| Hydrochloric Acid SCHEMBL28847345 | 0.77 | KDM4E (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110943253-A | High-voltage lithium ion battery combined electrolyte additive, electrolyte and battery thereof | 松山湖材料实验室 | 2020-03-31 | — | — | CN | claimed |
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4655304-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2025-12-03 | — | — | EP | disclosed |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | CEREVANCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-12258328-B2 | 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2025-03-25 | — | — | US | disclosed |
| EP-4514788-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| WO-2025007863-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-119241532-A | 1H-pyrazolo [4,3-c ] pyridine compound, composition and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2024217428-A1 | COMPOUND AND USE THEREOF IN TREATMENT OF CHRONIC HEPATITIS B, HEPATIC FIBROSIS AND LIVER CANCER | 河北乌图药业有限公司 | 2024-10-24 | — | — | WO | disclosed |
| WO-2003029244-A1 | PROCESS FOR PREPARING PYRIDYL-ALKYLSULFONYL PYRAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| EP-1298116-A1 | Process for preparing alkanesulfonyl pyridines | Pfizer Products Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6531492-B1 | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents | PFIZER INC. | 2003-03-11 | — | — | US | disclosed |
| US-6506779-B1 | useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock. | PFIZER INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1259504-A1 | PYRAZOLE ETHER DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1233959-A1 | HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | Pfizer Products Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020058681-A1 | Pyrazole ether derivatives as anti-inflammatory/analgesic agents | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2001064669-A1 | PYRAZOLE ETHER DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PRODUCTS INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040216-A1 | HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-1104758-A1 | Acetylene derivatives as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058681-A1 | Pyrazole ether derivatives as anti-inflammatory/analgesic agents | PTGER3, PTGER1, P2RX3 | ENPP2 1271/4885PTGS2 96/4885KCNH2 2592/4885 |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | GPR55, GPR68, GPR65 | ENPP2 479/4885PTGS2 1245/4885KCNH2 1614/4885 |
| US-12258328-B2 | 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | ENPP2 4199/4885PTGS2 3556/4885KCNH2 2663/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | ENPP2 155/4885PTGS2 142/4885KCNH2 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.